Haemonetics Corporation (HAE)

Payables turnover

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Cost of revenue (ttm)	US$ in thousands	611,866	646,008	649,396	638,995	621,814	598,290	586,501	578,435	553,563	534,087	508,697	486,446	487,694	502,225	501,135	487,521	472,625	454,338	465,144	486,968
Payables	US$ in thousands	—	62,990	69,242	76,929	73,358	56,845	80,160	78,134	63,929	63,769	61,484	57,907	58,371	51,175	44,969	49,131	50,293	42,979	49,071	48,459
Payables turnover		—	10.26	9.38	8.31	8.48	10.52	7.32	7.40	8.66	8.38	8.27	8.40	8.36	9.81	11.14	9.92	9.40	10.57	9.48	10.05

March 31, 2025 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $611,866K ÷ $—K
= —

Haemonetics Corporation's payables turnover ratio measures how efficiently the company is managing its accounts payable by comparing the amount of purchases made on credit to the average accounts payable balance over a specific period.

Looking at the data provided, we observe fluctuations in Haemonetics Corporation's payables turnover ratio over the reported periods. The payables turnover ratio ranged from a high of 11.14 in September 30, 2021, to a low of 7.32 in September 30, 2023.

A high payables turnover ratio indicates that Haemonetics is paying off its suppliers more frequently within the year, which could suggest favorable liquidity and strong relationships with suppliers. Conversely, a low payables turnover ratio may imply that the company is taking longer to settle its accounts payable, which could result in strained relationships with suppliers or inefficiencies in managing working capital.

It is important to consider industry norms and compare Haemonetics' payables turnover ratio with its competitors to gain a better understanding of its performance in managing accounts payable. Additionally, analyzing trends over time can provide insight into the company's payment policies and efficiency in managing working capital.

The absence of data for March 31, 2025, limits the current analysis, but monitoring future payables turnover ratios will be crucial to track any changes in Haemonetics Corporation's accounts payable management.